From:	[mailto:	@novartis com

Sent: Monday, May 04, 2015 11:25 AM

To: (CAB-ANDRIUKAITIS)
Cc: (CAB-ANDRIUKAITIS)

**Subject:** RE: Personal and non-transferable invitation: Fostering Creativity in Europe—a New Approach to Innovation and Healthcare

Dear	
Deal	5

Thank you very much for your interest in our event, we would be pleased to welcome Members of the Cabinet on May 27 at "Fostering Creativity in Europe—A New Approach to Innovation and Healthcare".

We also invited Ms Nathalie Chaze and Ms Annika Nowak, and we truly hope they can attend the event.

We will communicate additional details about the event in the coming weeks. Meanwhile, we would appreciate if you could let us know whom of Members of the Cabinet would be available to join us (for logistic purposes).

Should you have further questions, please do not hesitate to contact us.

With kind regards,

From: @ec.europa.eu

@ec.europa.eu

**Sent:** Thursday, April 30, 2015 9:52 AM

To: Gherman, Claudia

Cc: @ec.europa.eu

Subject: FW: Personal and non-transferable invitation: Fostering Creativity

in Europe—a New Approach to Innovation and Healthcare

## Good morning,

On behalf of Mr. Arunas Vinciunas, the Head of the Cabinet of Commissioner ANDRIUKAITIS, I would like to thank you for this kind invitation.

Unfortunately, due to the busy agenda Mr. Vinciunas will not be able to attend the event.

But the Member of the Cabinet would be able to replace him if that would be OK for you.

Please let me know,

Best regards,

Head of the Cabinet



## **European Commission**

Cabinet of Commissioner Vytenis Andriukaitis Health and Food Safety

BERL +32 229

@ec.europa.eu

From:

[mailto @novartis.com]
Sent: Wednesday, April 29, 2015 5:41 PM
To: VINCIUNAS Arunas (CAB-ANDRIUKAITIS)

Cc: @google.com

**Subject:** Personal and non-transferable invitation: Fostering Creativity in Europe—a New Approach to

Innovation and Healthcare

Dear Mr Arunas Vinciunas,

As Healthcare is facing a technological paradigm shift that has the potential to transform the lives of millions of European citizens, Novartis and Google Life Sciences wish to bring together key Brussels stakeholders to discuss the policy challenges for health innovation in all its different forms:

- What are the latest trends in health innovation? How can it contribute to improve healthcare delivery and patients' outcomes on a cost-effective basis?
- Is the EU regulatory and economic environment fit

for purpose in terms of incentives to and uptake of innovation? Can Europe become a creativity hub for disruptive innovation in healthcare?

Novartis and Google Life Sciences request the pleasure of your company at this informal event featuring two exceptional speakers who will set the scene for discussion:

- Novartis'

  Discovery & Investigative Safety and
  Therapeutic Areas in Preclinical Safety at Novartis
  Institutes for BioMedical Research (NIBR).
- Life Sciences.

The roundtable will take place on Wednesday, May 27<sup>th</sup>, from 12.30 to 14.00, in the Hessen Representation (Rue Montoyer 21, 1000 Brussels).

The session will include a small number of selected decision-makers and key opinion leaders who contribute to shaping the European policy landscape in the field of health innovation. To ensure an open, lively discussion, this invitation is personal and nontransferable. Discussions will follow Chatham House rules.

We would be delighted if you chose to attend this high-level event. Thanks for confirming your attendance to <a href="mailto:@novartis.com">@novartis.com</a> by Wednesday 20<sup>th</sup> May.

We look forward to hearing from you and remain at your disposal should you wish for further information.

Sincerely yours,

Brussels Public Affairs Office Google Novartis

Novartis European Public Affairs Rue du Trône 108 B-1050 Brussels Tel +32 (0)2

@novartis.com

www.novartis.com





Annika Nowak
European Commission
Rue de la Loi 200
B-1049 Brussels

Brussels, 29th April 2015

Re: Personal and non-transferable invitation to a high-level roundtable on Wednesday, May 27th in Brussels: Fostering Creativity in Europe—a New Approach to Innovation and Healthcare.

Dear Ms Annika Nowak,

Healthcare is facing a technological paradigm shift that has the potential to transform the lives of millions of European citizens. Whilst we see personalized medicines, cancer immunotherapies, and genome editing bringing targeted therapies to patients, the ongoing ICT revolution is not only changing the way medicine is delivered (e.g., through health applications, e-prescriptions) but also opening exciting areas for healthcare innovation in Europe. More and more, the astute combination of healthcare and digital innovation is bringing a new generation of therapeutic solutions that can improve patients' outcomes.

Novartis and Google Life Sciences wish to bring together key Brussels stakeholders to discuss the policy challenges for health innovation in all its different forms:

- What are the latest trends in health innovation? How can it contribute to improve healthcare delivery and patients' outcomes on a cost-effective basis?
- Is the EU regulatory and economic environment fit for purpose in terms of incentives to and uptake of innovation? Can Europe become a creativity hub for disruptive innovation in healthcare?

Novartis and Google Life Sciences request the pleasure of your company at this informal event featuring two exceptional speakers who will set the scene for discussion:

Novartis Institutes for BioMedical
Research (NIBR). With more than 22 years of experience in drug development,
will discuss the challenges of pharmaceutical R&D and unveil today's exciting
research projects towards tomorrow's medicine.

the mission of G —and how his te	is king on a wide-sp soogle Life Science eam is seeking to to to marshal the late	es—to help mo partner with me	thcare-relate ve health ca dical expert	ed projects. are from rea ts, patient gr	will ctive to pr oups, and	discuss roactive
	e place on Wedr ontoyer 21, 1000 B		7 <sup>th</sup> , from 12	2.30 to 14.00	), in the	Hessen

The session will include a small number of selected decision-makers and key opinion leaders who contribute to shaping the European policy landscape in the field of health innovation. To ensure an open, lively discussion, this invitation is personal and nontransferable. Discussions will follow Chatham House rules.

We would be delighted if you chose to attend this high-level event. Thanks for confirming your attendance to <a href="mailto:monoser: 20"><u>@novartis.com</u></a> by Wednesday 20<sup>th</sup> May.

We look forward to hearing from you and remain at your disposal should you wish for further information.

Sincerely yours,

EU Relations & Brussels Public Affairs Office Novartis

Google

From: [mailto @novartis.com]

Sent: Monday, May 11, 2015 3:39 PM

To: (CAB-ANDRIUKAITIS)

Subject: FW: Personal and non-transferable invitation: Fostering Creativity in Europe—a

New Approach to Innovation and Healthcare

Dear ,

It was a pleasure talking to you today and, as you suggested, I am forwarding you the invitation for Ms Nathalie Chaze to our event *Fostering Creativity in Europe—A New Approach to Innovation and Healthcare*.

I would sincerely appreciate if you could let me know at your earliest convenience if she would be available to attend our event.

Thank you very much for considering my request!

With warm regards,

From:

Sent: Wednesday, April 29, 2015 5:39 PM

To: @ec.europa.eu

Cc: @google.com

Subject: Personal and non-transferable invitation: Fostering Creativity in Europe—a New

Approach to Innovation and Healthcare

Dear Ms Nathalie Chaze,

As Healthcare is facing a technological paradigm shift that has the potential to transform the lives of millions of European citizens, Novartis and Google Life Sciences wish to bring together key Brussels stakeholders to discuss the policy challenges for health innovation in all its different forms:

- What are the latest trends in health innovation? How can it contribute to improve healthcare delivery and patients' outcomes on a cost-effective basis?
- Is the EU regulatory and economic environment fit for purpose in terms of incentives to and uptake of innovation? Can Europe become a creativity hub for disruptive innovation in healthcare?

Novartis and Google Life Sciences request the pleasure of your company at this informal event featuring two exceptional speakers who will set the scene for discussion:

Novartis Institutes for BioMedical Research (NIBR).

Google Life Sciences.

The roundtable will take place on Wednesday, May 27<sup>th</sup>, from 12.30 to 14.00, in the Hessen Representation (Rue Montoyer 21, 1000 Brussels).

The session will include a small number of selected decision-makers and key opinion leaders who contribute to shaping the European policy landscape in the field of health innovation. To ensure an open, lively discussion, this invitation is personal and nontransferable. Discussions will follow Chatham House rules.

We would be delighted if you chose to attend this high-level event. Thanks for confirming your attendance to <a href="mailto:monoseta">monovartis.com</a> by Wednesday 20<sup>th</sup> May.

We look forward to hearing from you and remain at your disposal should you wish for further information.

Sincerely yours,

Brussels Public Affairs Office Novartis

Google

Novartis European Public Affairs Rue du Trône 108 B-1050 Brussels Tel +32 (0)2

@novartis.com

www.novartis.com





Nathalie Chaze European Commission Rue de la Loi 200 B-1049 Brussels

Brussels, 29th April 2015

Re: Personal and non-transferable invitation to a high-level roundtable on Wednesday, May 27th in Brussels: Fostering Creativity in Europe—a New Approach to Innovation and Healthcare.

Dear Ms Nathalie Chaze,

Healthcare is facing a technological paradigm shift that has the potential to transform the lives of millions of European citizens. Whilst we see personalized medicines, cancer immunotherapies, and genome editing bringing targeted therapies to patients, the ongoing ICT revolution is not only changing the way medicine is delivered (e.g., through health applications, e-prescriptions) but also opening exciting areas for healthcare innovation in Europe. More and more, the astute combination of healthcare and digital innovation is bringing a new generation of therapeutic solutions that can improve patients' outcomes.

Novartis and Google Life Sciences wish to bring together key Brussels stakeholders to discuss the policy challenges for health innovation in all its different forms:

- What are the latest trends in health innovation? How can it contribute to improve healthcare delivery and patients' outcomes on a cost-effective basis?
- Is the EU regulatory and economic environment fit for purpose in terms of incentives to and uptake of innovation? Can Europe become a creativity hub for disruptive innovation in healthcare?

Novartis and Google Life Sciences request the pleasure of your company at this informal event featuring two exceptional speakers who will set the scene for discussion:

Novartis Institutes for BioMedical
Research (NIBR). With more than 22 years of experience in drug development,
will discuss the challenges of pharmaceutical R&D and unveil today's exciting
research projects towards tomorrow's medicine.

of scientists working on a wide-spectrum of health the mission of Google Life Sciences—to help mov—and how his team is seeking to partner with med sciences sector to marshal the latest technological	e health care from reactive to proactive ical experts, patient groups, and the life	
The roundtable will take place on Wednesday, May $27^{th}$ , from 12.30 to 14.00, in the Hessen Representation (Rue Montoyer 21, 1000 Brussels).		
The session will include a small number of selected de- who contribute to shaping the European policy landscapensure an open, lively discussion, this invitation is personal follow Chatham House rules.	be in the field of health innovation. To	
We would be delighted if you chose to attend this high-lattendance to <a href="mailto:ome">ome on the control of the control o</a>		
We look forward to hearing from you and remain at you information.	ur disposal should you wish for further	
Sincerely yours,		
Brussels Public Affairs Office Novartis	Google	